1. Research Framework
1.1. Research Objective
1.2. Product Type Overview
1.3. Market Segmentation
2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary and Secondary Sources
2.2. Quantitative Research
2.2.1. Primary and Secondary Sources
2.3. Breakdown of Primary Research Respondents
2.3.1. Secondary Research
2.3.2. Primary Research
2.4. Breakdown of Primary Research Respondents, By Industry Participants
2.5. Key Questionnaire asked during Primary Interviews
2.6. Key Primary Responses
2.7. Market Size Estimation
2.8. Assumption for the Study
2.9. Market Breakdown & Data Triangulation
3. Executive Summary
4. Global Generic Drugs Market Industry Insights
4.1. Industry Value Chain/Supply Chain
4.2. DROC Analysis
4.2.1. Growth Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.2.4. Challenges
4.3. Recent Developments / Technical Landscape
4.4. Regulatory Framework
4.5. Porters Five Forces Analysis
5. Global Generic Drugs Market Overview, 2018-2028
5.1. Market Size & Forecast
5.1.1. By Value (USD Billion)
5.2. Market Share & Forecast
5.2.1. By Product Type
5.2.1.1. Simple Generics
5.2.1.2. Super Generics
5.2.1.3. Biosimilars
5.2.2. By Route of Administration
5.2.2.1. Oral
5.2.2.2. Topical
5.2.2.3. Injectable
5.2.2.4. Others
5.2.3. By Application
5.2.3.1. Cardiovascular Products
5.2.3.2. Anti-infective Drugs
5.2.3.3. Anti-arthritis Drugs
5.2.3.4. Central Nervous System Drugs
5.2.3.5. Anti-Cancer Drugs
5.2.3.6. Respiratory Products
5.2.3.7. Other
5.2.4. By Distribution Channel
5.2.4.1. Hospitals/Clinics
5.2.4.2. Retail Pharmacies
5.2.4.3. Other
5.2.5. Region
5.2.5.1. North America
5.2.5.2. Europe
5.2.5.3. Asia-Pacific
5.2.5.4. Latin America
5.2.5.5. Middle East & Africa
6. North America Generic Drugs Market Overview, 2018-2028
6.1. Market Size & Forecast
6.1.1. By Value (USD Billion)
6.2. Market Share & Forecast
6.2.1. By Product Type
6.2.2. By Route of Administration
6.2.3. By Application
6.2.4. By Distribution Channel
6.2.5. By Country
6.2.5.1. United States
6.2.5.2. Canada
7. Europe Generic Drugs Market Overview, 2018-2028
7.1. Market Size & Forecast
7.1.1. By Value (USD Billion)
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By Route of Administration
7.2.3. By Application
7.2.4. By Distribution Channel
7.2.5. By Country
7.2.5.1. Germany
7.2.5.2. France
7.2.5.3. Italy
7.2.5.4. Spain
7.2.5.5. UK
7.2.5.6. Netherlands
7.2.5.7. Rest of Europe
8. Asia-Pacific Generic Drugs Market Overview, 2018-2028
8.1. Market Size & Forecast
8.1.1. By Value (USD Billion)
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Route of Administration
8.2.3. By Application
8.2.4. By Distribution Channel
8.2.5. By Country
8.2.5.1. China
8.2.5.2. India
8.2.5.3. Japan
8.2.5.4. South Korea
8.2.5.5. Rest of Asia-Pacific
9. Latin America Generic Drugs Market Overview, 2018-2028
9.1. Market Size & Forecast
9.1.1. By Value (USD Billion)
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By Route of Administration
9.2.3. By Application
9.2.4. By Distribution Channel
9.2.5. By Country
9.2.5.1. Argentina
9.2.5.2. Brazil
9.2.5.3. Mexico
9.2.5.4. Rest of Latin America
10. Middle East & Africa Generic Drugs Market Overview, 2018-2028
10.1. Market Size & Forecast
10.1.1. By Value (USD Billion)
10.2. Market Share & Forecast
10.2.1. By Product Type
10.2.2. By Route of Administration
10.2.3. By Application
10.2.4. By Distribution Channel
10.2.5. By Country
10.2.5.1. Saudi Arabia
10.2.5.2. South Africa
10.2.5.3. UAE
10.2.5.4. Rest of Middle East & Africa
11. Competitive Landscape
11.1.1. List of Key Producers and Their Offerings
11.1.2. Market Share / Ranking Analysis (2021)
11.1.3. Competitive Benchmarking, By Operating Parameters
11.1.4. Key Developments & Growth Strategies
11.1.4.1. Mergers & Acquisitions
12. COVID-19 Impact
13. Company Profiles (Company Overview, Financial Matrix, Key Product Type landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *
13.1. Teva Pharmaceutical Industries
13.2. Fresenius Kabi
13.3. Sandoz, a Novartis Divison
13.4. Mylan N.V.
13.5. Sanofi S.A.
13.6. Sun Pharmaceutical Industries Limited
13.7. Mallinckrodt Pharmaceuticals
13.8. Stada Arzneimittel AG
13.9. Aurobindo Pharma Limited
13.10. Endo International plc.
13.11. Aspen Pharmacare Holdings Limited
13.12. Dr. Reddy's Laboratories
13.13. Cipla Limited
13.14. Hikma Pharmaceuticals plc.
13.15. Piramal Pharma Solutions
13.16. LUPIN Limited
13.17. Sawai Pharmaceutical Co. Ltd.
13.18. Amneal Pharmaceuticals, Inc.
13.19. Glenmark Pharmaceuticals Limited
13.20. Torrent Pharmaceuticals Ltd.
13.21. Other Prominent Players
14. Key Strategic Recommendations
* Financial information of non-listed Companies will be provided as per availability
**The segmentation and the companies are subjected to modifications based on in-depth study during the final deliverable.